The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
After the FTC’s November action, several manufacturers de-listed patents and three top drugmakers announced they would cap inhaler out-of-pocket costs at $35. “By filing bogus patent listings, pharma ...
At the center of the issue is the Orange Book, an FDA publication containing patents relevant to brand-name pharmaceuticals. If a brand-name manufacturer decides to contest a challenge to an ...
The Federal Trade Commission said it is challenging hundreds of alleged "junk ... The FTC also notified the Food and Drug Administration about the challenges. The FDA manages patent listings ...
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended ... disputing more than 300 patent listings in its Orange Book covering 20 brands ...
The U.S. Food and Drug Administration first approved Ozempic in 2017 Novo Nordisk responded today to the U.S. Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to ...
FTC’s Warning Letters Targets Orange Book Patents Claiming ... along with two patents related to Victoza. Calling these listings “junk patent filings,” the FTC insists that these ...
Auto sales should be included in the latest proposal on junk fees, consumer advocates told an FTC public hearing on unfair or deceptive fees today. Some auto dealers would be exempt from the proposed ...